| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 1999;118:1136-1152
© 1999 Mosby, Inc.
BASIC SCIENCE REVIEW |
From the Hamon Center for Therapeutic Oncology Research,c University of Texas Southwestern Medical Center, Dallas, Tex, The Prince Charles Hospital,a Brisbane, Australia, and the Department of Clinical Preventive Service,b Nagoya University Hospital, Nagoya, Japan.
Supported by Lung Cancer SPORE P50 CA70907.
Address for reprints: John D. Minna, MD, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75235-8593 (E-mail: minna{at}simmons.swmed.edu ).
Lung cancer is the largest cancer killer of men and women in the united states. In addition to the progress made from antismoking primary prevention measures, new tools to help treat patients with lung cancer are emerging from the rapid advances in knowledge of the molecular pathogenesis of lung cancer. These tools include molecular and cellular biology and are starting to provide an insight into how the tumor cell, by altering oncogenes and tumor suppressor genes, achieves growth advantage, uncontrolled proliferation and metastatic behavior via disruption of key cell-cycle regulators and signal transduction cascades. Moreover, new knowledge is being developed in terms of the molecular definition of individual susceptibility to tobacco smoke carcinogens. These tools are being translated into clinical strategies to complement surgery, radiotherapy, and chemotherapy and also to assist in primary and secondary prevention efforts. This review summarizes current knowledge of the molecular pathogenesis of lung cancer. From this we know that respiratory epithelial cells require many genetic alterations to become invasive and metastatic cancer. We can detect cells with a few such changes in current and former smokers, offering the opportunity to intercede with a biomarker-monitored prevention and early detection effort. This will be coupled with new advances in computed tomography–based screening. Finally, because the molecular alterations are known, new mechanism-based therapies are being developed and brought to the clinic, including new drugs, vaccines, and gene therapy, which also must be integrated with standard therapies.
This article has been cited by other articles:
|
|
 |
|
  P. H. Hartel, A. L. Shackelford, J. V. Hartel, and S. L. Wenger Del(5q) Is Associated With Clinical and Histological Parameters in Small Cell Neuroendocrine Lung Carcinoma International Journal of Surgical Pathology, October 1, 2008; 16(4): 419 - 423. [Abstract] [PDF]
|
|
|
|
 |
|
 X. Zhang and A. Chang Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer J. Med. Genet., March 1, 2007; 44(3): 166 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Pajares, I. Zudaire, M. D. Lozano, J. Agorreta, G. Bastarrika, W. Torre, A. Remirez, R. Pio, J. J. Zulueta, and L. M. Montuenga Molecular profiling of computed tomography screen-detected lung nodules shows multiple malignant features. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 373 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Esposito, A Baldi, A De Luca, G Tonini, B Vincenzi, D Santini, P Persichetti, A Mancini, G Citro, F Baldi, et al. Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer J. Clin. Pathol., July 1, 2005; 58(7): 734 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Liao, R. Komaki, L. Milas, C. Yuan, M. Kies, J. Y. Chang, M. Jeter, T. Guerrero, G. Blumenschien, C. M. Smith, et al. A Phase I Clinical Trial of Thoracic Radiotherapy and Concurrent Celecoxib for Patients with Unfavorable Performance Status Inoperable/Unresectable Non-Small Cell Lung Cancer Clin. Cancer Res., May 1, 2005; 11(9): 3342 - 3348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Shigematsu, L. Lin, T. Takahashi, M. Nomura, M. Suzuki, I. I. Wistuba, K. M. Fong, H. Lee, S. Toyooka, N. Shimizu, et al. Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers J Natl Cancer Inst, March 2, 2005; 97(5): 339 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Humphrey, S. Teutsch, and M. Johnson Lung Cancer Screening with Sputum Cytologic Examination, Chest Radiography, and Computed Tomography: An Update for the U.S. Preventive Services Task Force Ann Intern Med, May 4, 2004; 140(9): 740 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Zhang, S. R. Kleeberger, and S. P. Reddy DEP-induced fra-1 expression correlates with a distinct activation of AP-1-dependent gene transcription in the lung Am J Physiol Lung Cell Mol Physiol, February 1, 2004; 286(2): L427 - L436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Spira and D. S. Ettinger Multidisciplinary Management of Lung Cancer N. Engl. J. Med., January 22, 2004; 350(4): 379 - 392. [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Criss Molecular Mechanisms of Toxic Chemicals Indoor and Built Environment, December 1, 2003; 12(6): 395 - 399. [Abstract] [PDF]
|
|
|
|
 |
|
 H.-Y. Lee, H. Srinivas, D. Xia, Y. Lu, R. Superty, R. LaPushin, C. Gomez-Manzano, A. M. Gal, G. L. Walsh, T. Force, et al. Evidence That Phosphatidylinositol 3-Kinase- and Mitogen-activated Protein Kinase Kinase-4/c-Jun NH2-terminal Kinase-dependent Pathways Cooperate to Maintain Lung Cancer Cell Survival J. Biol. Chem., June 20, 2003; 278(26): 23630 - 23638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Haga, K. Hiroshima, A. Iyoda, K. Shibuya, F. Shimamura, T. Iizasa, T. Fujisawa, and H. Ohwada Ki-67 expression and prognosis for smokers with resected stage i Non-Small cell lung cancer Ann. Thorac. Surg., June 1, 2003; 75(6): 1727 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. M. Reddy and B. T. Mossman Role and regulation of activator protein-1 in toxicant-induced responses of the lung Am J Physiol Lung Cell Mol Physiol, December 1, 2002; 283(6): L1161 - L1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Dy and A. A. Adjei Novel Targets for Lung Cancer Therapy: Part I J. Clin. Oncol., June 15, 2002; 20(12): 2881 - 2894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. McDoniels-Silvers, C. F. Nimri, G. D. Stoner, R. A. Lubet, and M. You Differential Gene Expression in Human Lung Adenocarcinomas and Squamous Cell Carcinomas Clin. Cancer Res., April 1, 2002; 8(4): 1127 - 1138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gonzalez-Quevedo, P. Iniesta, A. Moran, C. de Juan, A. Sanchez-Pernaute, C. Fernandez, A. Torres, E. Diaz-Rubio, J.-L. Balibrea, and M. Benito Cooperative Role of Telomerase Activity and p16 Expression in the Prognosis of Non-Small-Cell Lung Cancer J. Clin. Oncol., January 1, 2002; 20(1): 254 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. H. Kantarci, T. G. Lesnick, P. Yang, R. L. Meyer, D. D. Hebrink, C. T. McMurray, and B. G. Weinshenker Myeloperoxidase -463 (G(R)A) Polymorphism Associated With Lower Risk of Lung Cancer Mayo Clin. Proc., January 1, 2002; 77(1): 17 - 22. [Abstract] [PDF]
|
|
|
|
 |
|
 G. H. Fisher, S. L. Wellen, D. Klimstra, J. M. Lenczowski, J. W. Tichelaar, M. J. Lizak, J. A. Whitsett, A. Koretsky, and H. E. Varmus Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes Genes & Dev., December 15, 2001; 15(24): 3249 - 3262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Palmarini and H. Fan Retrovirus-Induced Ovine Pulmonary Adenocarcinoma, an Animal Model for Lung Cancer J Natl Cancer Inst, November 7, 2001; 93(21): 1603 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Hirsch, W. A. Franklin, A. F. Gazdar, and P. A. Bunn Jr. Early Detection of Lung Cancer: Clinical Perspectives of Recent Advances in Biology and Radiology Clin. Cancer Res., January 1, 2001; 7(1): 5 - 22. [Abstract] [Full Text]
|
|
|
|
|
|
E. F. Patz, P. C. Goodman, and G. Bepler Screening for Lung Cancer N. Engl. J. Med., November 30, 2000; 343(22): 1627 - 1633. [Full Text] [PDF]
|
|
|
|
|
|
D. N. Carney and H. H. Hansen Non-Small-Cell Lung Cancer -- Stalemate or Progress? N. Engl. J. Med., October 26, 2000; 343(17): 1260 - 1262. [Full Text]
|
|
|
|
 |
|
 L. Girard, S. Zöchbauer-Müller, A. K. Virmani, A. F. Gazdar, and J. D. Minna Genome-wide Allelotyping of Lung Cancer Identifies New Regions of Allelic Loss, Differences between Small Cell Lung Cancer and Non-Small Cell Lung Cancer, and Loci Clustering Cancer Res., September 1, 2000; 60(17): 4894 - 4906. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
